Top

Published in:

Open Access 13-05-2023 | Systemic Sclerosis | Commentary

Living with Systemic Sclerosis: A Patient and Physician Perspective

Authors: Arissa Young, Brittany Rudy, Elizabeth R Volkmann

Published in: Rheumatology and Therapy | Issue 4/2023

Abstract

The fears associated with being diagnosed with a disease unfamiliar to many, systemic sclerosis, is described by a patient living with systemic sclerosis. The patient, a coauthor, also describes the challenges of being a young person diagnosed with a chronic and, at times, debilitating disease. Despite initially being told that she had 6 months to live, she has embraced life and has become a fierce advocate for others living with systemic sclerosis. The physician perspective is provided by two rheumatologists who specialize in systemic sclerosis and work at a scleroderma center of excellence. This section details the current challenges in diagnosing systemic sclerosis early and the dangers of a delayed diagnosis. It also reviews the importance of multi-disciplinary specialty centers in the care of patients with systemic sclerosis as well as empowering patients through education.

Fan Y, Bender S, Shi W, Zoz D. Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States. J Manag Care Spec Pharm. 2020;26(12):1539–47. https://doi.org/10.18553/JMCP.2020.20136.CrossRefPubMed

Distler O, Allanore Y, Denton CP, Matucci-Cerinic M, Pope JE, Hinzmann B, Khanna D. Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. Rheumatology. 2018;57(5):813–7. https://doi.org/10.1093/RHEUMATOLOGY/KEX504.CrossRefPubMedPubMedCentral

Volkmann ER, Andréasson K, Smith V. Systemic sclerosis. Lancet. 2023;401(10373):304–18. https://doi.org/10.1016/S0140-6736(22)01692-0.CrossRefPubMed

Johnson SR, Carette S, Dunne JV. Scleroderma: health services utilization from patients’ perspective. J Rheumatol. 2006;33(6):1123–7.PubMed

Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, Senécal JL. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008;58(12):3902–12. https://doi.org/10.1002/art.24038.CrossRefPubMed

Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, Sampaio-Barros P. Preliminary criteria for the very early diagnosis of systemic sclerosis: Results of a Delphi consensus study from EULAR scleroderma trials and research group. Ann Rheum Dis. 2011;70(3):476–81. https://doi.org/10.1136/ard.2010.136929.CrossRefPubMed

“Find a treatment center.” National Scleroderma Foundation, 2022, https://scleroderma.org/find-a-treatment-center/. January 20, 2023.

Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respir Rev. 2013;22(127):6–19. https://doi.org/10.1183/09059180.00005512.CrossRefPubMedPubMedCentral

Volkmann E. Systemic sclerosis. Lancet. 2023;401(10373):304–18. https://doi.org/10.1016/S0140-6736(22)01692-0.Systemic.CrossRefPubMed

10.

Liem SIE, Vlieland TPMV, Schoones JW, de Vries-Bouwstra JK. The effect and safety of exercise therapy in patients with systemic sclerosis: a systematic review. Rheumatol Adv Pract. 2019;3(2):1–13. https://doi.org/10.1093/rap/rkz044.CrossRef

11.

Stefanantoni K, Sciarra I, Iannace N, Vasile M, Caucci M, Sili Scavalli A, Massimiani MP, Passi L, Maset L, Riccieri V. Occupational therapy integrated with a self-administered stretching program on systemic sclerosis patients with hand involvement. Clin Exp Rheumatol. 2016;34(5):157–61.PubMed

12.

Benrud-Larson LM, Haythornthwaite JA, Heinberg LJ, Boling C, Reed J, White B, Wigley FM. The impact of pain and symptoms of depression in scleroderma. Pain. 2002;95(3):267–75. https://doi.org/10.1016/S0304-3959(01)00409-2.CrossRefPubMed

13.

Stöcker JK, Schouffoer AA, Spierings J, Schriemer MR, Potjewijd J, De Pundert L, Van Den Ende CHM. Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaud’s phenomenon and digital ulcers in patients with systemic sclerosis. Rheumatology. 2022;61(4):1476–86. https://doi.org/10.1093/rheumatology/keab537.CrossRefPubMed

14.

Keane N, Ghannam A, Fragkos KC, Rahman F. Oral, enteral and parenteral nutritional therapies in scleroderma: a systematic review. Clinical Nutrition ESPEN. 2022;51:174–84. https://doi.org/10.1016/j.clnesp.2022.06.108.CrossRefPubMed

15.

Nakayama A, Tunnicliffe DJ, Thakkar V, Singh-Grewal D, O’Neill S, Craig JC, Tong A. Patients’ perspectives and experiences living with systemic sclerosis: a systematic review and thematic synthesis of qualitative studies. J Rheumatol. 2016;43(7):1363–75. https://doi.org/10.3899/jrheum.151309.CrossRefPubMed

16.

Distler O, Assassi S, Cottin V, Cutolo M, Danoff SK, Denton CP, Maher TM. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J. 2020. https://doi.org/10.1183/13993003.02026-2019.CrossRefPubMedPubMedCentral

17.

Khanna D, Lescoat A, Roofeh D, Bernstein EJ, Kazerooni EA, Roth MD, Denton CP. Systemic sclerosis-associated interstitial lung disease: how to incorporate two food and drug administration-approved therapies in clinical practice. Arthr Rheumatol. 2022;74(1):13–27. https://doi.org/10.1002/art.41933.CrossRef

18.

Tashkin DP, Volkmann ER, Tseng CH, Roth MD, Khanna D, Furst DE, Elashoff RM. Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease: results of scleroderma lung study II. Chest. 2017;151(4):813–20. https://doi.org/10.1016/j.chest.2016.11.052.CrossRefPubMed

19.

Volkmann ER, Tashkin DP, Leng M, Kim GHJ, Goldin J, Roth MD. Association of symptoms of gastroesophageal reflux, esophageal dilation, and progression of systemic sclerosis-related interstitial lung disease. Arthritis Care Res (Hoboken). 2022. https://doi.org/10.1002/acr.25070.CrossRefPubMedPubMedCentral

20.

Hughes M, Allanore Y, Baron M, Galdo F, Del Denton CP, Frech T, Matucci-cerinic M. Viewpoint Proton pump inhibitors in systemic sclerosis : a reappraisal to optimise treatment of gastro-oesophageal reflux disease. 2022;4: 795–803.

21.

Poole JL, Mendelson C, Skipper B, Khanna D. Taking charge of systemic sclerosis: a pilot study to assess the effectiveness of an internet self-management program. Arthritis Care Res. 2014;66(5):778–82. https://doi.org/10.1002/acr.22192.CrossRef

22.

Landim SF, Bertolo MB, Marcatto de Abreu MF, Del Rio AP, Mazon CC, Marques-Neto JF, de Paiva Magalhães E. The evaluation of a home-based program for hands in patients with systemic sclerosis. J Hand Therapy. 2019;32(3):313–21. https://doi.org/10.1016/j.jht.2017.10.013.CrossRef

Title: Living with Systemic Sclerosis: A Patient and Physician Perspective
Authors: Arissa Young
Brittany Rudy
Elizabeth R Volkmann
Publication date: 13-05-2023
Publisher: Springer Healthcare
Keywords: Systemic Sclerosis
Scleroderma
Published in: Rheumatology and Therapy / Issue 4/2023
Print ISSN: 2198-6576
Electronic ISSN: 2198-6584
DOI: https://doi.org/10.1007/s40744-023-00555-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2023

Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial

Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study

Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis

Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry

Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials